Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study

被引：126

作者：

Kusumoto, Shigeru ^{[1
]}

Tanaka, Yasuhito ^{[2
,3
]}

Suzuki, Ritsuro ^{[4
]}

Watanabe, Takashi ^{[5
]}

Nakata, Masanobu ^{[6
]}

Takasaki, Hirotaka ^{[7
]}

Fukushima, Noriyasu ^{[8
]}

Fukushima, Takuya ^{[9
]}

Moriuchi, Yukiyoshi ^{[10
]}

Itoh, Kuniaki ^{[11
]}

Nosaka, Kisato ^{[12
]}

Choi, Ilseung ^{[13
]}

Sawa, Masashi ^{[14
]}

Okamoto, Rumiko ^{[15
]}

Tsujimura, Hideki ^{[16
]}

Uchida, Toshiki ^{[17
]}

Suzuki, Sachiko ^{[18
]}

Okamoto, Masataka ^{[19
]}

Takahashi, Tsutomu ^{[20
]}

Sugiura, Isamu ^{[21
]}

Onishi, Yasushi ^{[22
]}

Kohri, Mika ^{[23
]}

Yoshida, Shinichiro ^{[24
]}

Sakai, Rika ^{[25
]}

Kojima, Minoru ^{[26
]}

Takahashi, Hiroyuki ^{[27
]}

Tomita, Akihiro ^{[28
]}

Maruyama, Dai ^{[5
]}

Atsuta, Yoshiko ^{[4
]}

Tanaka, Eiji ^{[29
]}

Suzuki, Takayo ^{[30
]}

Kinoshita, Tomohiro ^{[31
]}

Ogura, Michinori ^{[17
]}

Mizokami, Masashi ^{[32
]}

Ueda, Ryuzo ^{[33
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi, Japan

[3] Nagoya City Univ, Grad Sch Med Sci, Liver Unit, Nagoya, Aichi, Japan

[4] Nagoya City Univ, Grad Sch Med Sci, Dept Hematopoiet Stem Cell Transplantat Data Mana, Nagoya, Aichi, Japan

[5] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[6] Sapporo Hokuyu Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan

[7] Kanagawa Canc Ctr, Dept Med Oncol, Yokohama, Kanagawa 2410815, Japan

[8] Saga Univ, Fac Med, Dept Internal Med, Div Hematol, Saga, Japan

[9] Nagasaki Univ, Atom Bomb Dis Inst, Atom Bomb Dis & Hibakusha Med Unit, Dept Hematol, Nagasaki, Japan

[10] Sasebo City Gen Hosp, Dept Hematol, Sasebo, Japan

[11] Natl Canc Ctr Hosp East, Div Hematol & Oncol, Kashiwa, Chiba, Japan

[12] Kumamoto Univ, Sch Med, Dept Hematol & Infect Dis, Kumamoto 860, Japan

[13] Natl Hosp Org, Kyushu Canc Ctr, Div Hematol, Fukuoka, Japan

[14] Anjo Kosei Hosp, Dept Hematol & Oncol, Anjo, Aichi, Japan

[15] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Chemotherapy, Tokyo, Japan

[16] Chiba Canc Ctr, Div Hematol Oncol, Chiba, Japan

[17] Nagoya Daini Red Cross Hosp, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[18] Natl Hosp Org, Hokkaido Canc Ctr, Dept Hematol, Sapporo, Hokkaido, Japan

[19] Fujita Hlth Univ, Sch Med, Dept Hematol & Med Oncol, Toyoake, Aichi 47011, Japan

[20] Shimane Univ Hosp, Dept Oncol Hematol, Izumo, Shimane, Japan

[21] Toyohashi Municipal Hosp, Div Hematol & Oncol, Toyohashi, Aichi, Japan

[22] Tohoku Univ Hosp, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan

[23] Saitama Med Univ, Int Med Ctr, Dept Hematol, Hidaka, Japan

[24] Natl Hosp Org, Nagasaki Med Ctr, Dept Hematol, Ohmura, Japan

[25] Yokohama City Univ, Med Ctr, Dept Hematol, Yokohama, Kanagawa, Japan

[26] Tokai Univ, Sch Med, Dept Hematol & Oncol, Isehara, Kanagawa 25911, Japan

[27] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Yokohama, Kanagawa, Japan

[28] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi 4648601, Japan

[29] Shinshu Univ, Sch Med, Dept Med, Matsumoto, Nagano 390, Japan

[30] Shiga Med Ctr Adults, Dept Hematol & Oncol, Moriyama, Japan

[31] Aichi Canc Ctr Hosp, Dept Hematol & Cell Therapy, Nagoya, Aichi 464, Japan

[32] Natl Ctr Global Hlth & Med, Res Ctr Hepatitis & Immunol, Ichikawa, Japan

[33] Aichi Med Univ, Sch Med, Dept Tumor Immunol, Nagoya, Aichi, Japan

来源：

CLINICAL INFECTIOUS DISEASES | 2015年 / 61卷 / 05期

关键词：

HBV DNA monitoring; HBV reactivation; resolved HBV infection; rituximab; preemptive antiviral therapy; RANDOMIZED CONTROLLED-TRIAL; CYTOTOXIC CHEMOTHERAPY; RECEIVING RITUXIMAB; MALIGNANT-LYMPHOMA; INFECTION; LAMIVUDINE; THERAPY; PATIENT; IMMUNOGENICITY; PROPHYLAXIS;

D O I：

10.1093/cid/civ344

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. There is no standard management of reactivation of hepatitis B virus (HBV) infection in HBV-resolved patients without hepatitis B surface antigen (HBsAg), but with antibodies against hepatitis B core antigen and/or antibodies against HBsAg (anti-HBs). Methods. We conducted a prospective observational study to evaluate the occurrence of HBV reactivation by serial monthly monitoring of HBV DNA and to establish preemptive therapy guided by this monitoring in B-cell non-Hodgkin lymphoma (B-NHL) treated with rituximab plus corticosteroid-containing chemotherapy (R-steroid-chemo). The primary endpoint was the incidence of HBV reactivation defined as quantifiable HBV DNA levels of >= 11 IU/mL. Results. With a median HBV DNA follow-up of 562 days, HBV reactivation was observed in 21 of the 269 analyzed patients. The incidence of HBV reactivation at 1.5 years was 8.3% (95% confidence interval, 5.5-12.4). No hepatitis due to HBV reactivation was observed in patients who received antiviral treatment when HBV DNA levels were between 11 and 432 IU/mL. An anti-HBs titer of <10 mIU/mL and detectable HBV DNA remaining below the level of quantification at baseline were independent risk factors for HBV reactivation (hazard ratio, 20.6 and 56.2, respectively; P < .001). Even in 6 patients with a rapid increase of HBV due to mutations, the monthly HBV DNA monitoring was effective at preventing HBV-related hepatitis. Conclusions. Monthly monitoring of HBV DNA is useful for preventing HBV reactivation-related hepatitis among B-NHL patients with resolved HBV infection following R-steroid-chemo (UMIN000001299).

引用

页码：719 / 729

页数：11

共 50 条

[21] Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study
Ji, Dongmei
Cao, Junning
Hong, Xiaonan
Li, Junmin
Wang, Jianmin
Chen, Fangyuan
Wang, Chun
Zou, Shanhua
EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 243 - 250
[22] Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients
Marty, Celine
Adam, Jean-Philippe
Martel-Laferriere, Valerie
Doucet, Stephane
Martel, Dominic
SUPPORTIVE CARE IN CANCER, 2024, 32 (08)
[23] Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection
Kotake, Takeshi
Satake, Hironaga
Okita, Yoshihiro
Hatachi, Yukimasa
Hannada, Manniko
Omiya, Masatonno
Yasui, Hisateru
Hashida, Toru
Kaihara, Satoshi
Inokuma, Tetsuro
Tsuji, Akihito
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (01) : 63 - 68
[24] Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients
Watanabe, Masaaki
Shibuya, Akitaka
Takada, Juichi
Tanaka, Yoshiaki
Okuwaki, Yusuke
Minamino, Tsutomu
Hidaka, Hisashi
Nakazawa, Takahide
Koizumi, Wasaburo
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2010, 21 (04) : 333 - 337
[25] Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma
Liu, Wei-Ping
Zheng, Wen
Song, Yu-Qin
Ping, Ling-Yan
Wang, Gui-Qiang
Zhu, Jun
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (17) : 5165 - 5170
[26] Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab
Tan, Chia Jie
Kumar, Rajneesh
Koomanan, Narendran
Loo, Wei Sheng
Farid, Mohamad
Tao, Miriam
Somasundaram, Nagavalli
Poon, Eileen
Chan, Jason Yongsheng
Yang, Valerie Shiwen
Chang, Esther
Lim, Soon Thye
Chow, Wan Cheng
Chan, Alexandre
Tang, Tiffany
PHARMACOTHERAPY, 2021, 41 (04): : 332 - 341
[27] High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy
Zhong, S
Yeo, W
Schroder, C
Chan, PKS
Wong, WL
Ho, WM
Mo, F
Zee, B
Johnson, PJ
JOURNAL OF VIRAL HEPATITIS, 2004, 11 (01) : 55 - 59
[28] Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies
Yagci, Muenci
Ozkurt, Zuebeyde Nur
Yegin, Zeynep Arzu
Aki, Zeynep
Sucak, Guelsan Tuerkoez
Haznedar, Rauf
HEMATOLOGY, 2010, 15 (04) : 240 - 244
[29] Hepatitis B Virus Reactivation in Patients with Previously Resolved Hepatitis B Treated with Rituximab-Containing Chemotherapy for B-Cell Lymphoma
Cakmak, Erol
ERCIYES MEDICAL JOURNAL, 2018, 40 (01) : 28 - 34
[30] Risk Stratification for Hepatitis B Virus Reactivation in Kidney Transplant Recipients With Resolved HBV Infection
Tsai, Hsin-Ju
Wu, Ming-Ju
Chen, Cheng-Hsu
Yang, Sheng-Shun
Huang, Yi-Hsiang
Chang, Yan-Zin
Chang, Horng-Rong
Lee, Teng-Yu
TRANSPLANT INTERNATIONAL, 2023, 36

← 1 2 3 4 5 →